BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25566730)

  • 1. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R; Sigaud A; Azria M; Herrmann FR
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
    Chesnut CH; Majumdar S; Newitt DC; Shields A; Van Pelt J; Laschansky E; Azria M; Kriegman A; Olson M; Eriksen EF; Mindeholm L
    J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study.
    Rizzoli R; Chapurlat RD; Laroche JM; Krieg MA; Thomas T; Frieling I; Boutroy S; Laib A; Bock O; Felsenberg D
    Osteoporos Int; 2012 Jan; 23(1):305-15. PubMed ID: 21909729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior ankle fractures in postmenopausal women are associated with low areal bone mineral density and bone microstructure alterations.
    Biver E; Durosier C; Chevalley T; Herrmann FR; Ferrari S; Rizzoli R
    Osteoporos Int; 2015 Aug; 26(8):2147-55. PubMed ID: 25851699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
    Binkley N; Bone H; Gilligan JP; Krause DS
    Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.
    Burghardt AJ; Kazakia GJ; Sode M; de Papp AE; Link TM; Majumdar S
    J Bone Miner Res; 2010 Dec; 25(12):2558-71. PubMed ID: 20564242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
    Macdonald HM; Nishiyama KK; Hanley DA; Boyd SK
    Osteoporos Int; 2011 Jan; 22(1):357-62. PubMed ID: 20458576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: a 2-year case-control study.
    Zhu TY; Griffith JF; Qin L; Hung VW; Fong TN; Au SK; Tang XL; Kun EW; Kwok AW; Leung PC; Li EK; Tam LS
    Osteoporos Int; 2015 Jun; 26(6):1759-71. PubMed ID: 25736166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).
    Schafer AL; Burghardt AJ; Sellmeyer DE; Palermo L; Shoback DM; Majumdar S; Black DM
    Osteoporos Int; 2013 Oct; 24(10):2591-601. PubMed ID: 23589163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
    Cheung AM; Majumdar S; Brixen K; Chapurlat R; Fuerst T; Engelke K; Dardzinski B; Cabal A; Verbruggen N; Ather S; Rosenberg E; de Papp AE
    J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial.
    Jamal SA; Hamilton CJ; Eastell R; Cummings SR
    JAMA; 2011 Feb; 305(8):800-7. PubMed ID: 21343579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salmon calcitonin in the prevention of bone loss at perimenopause.
    Arnala I; Saastamoinen J; Alhava EM
    Bone; 1996 Jun; 18(6):629-32. PubMed ID: 8806006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
    Overgaard K; Lindsay R; Christiansen C
    Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.